The Latest

Bictegravir at CROI 2018: Switching Studies and Drug Resistance Analyses

Reports about bictegravir, the most recently approved integrase inhibitor, were included in an oral presentation and in several posters at CROI 2018.

By Simon Collins for HIV i-Base

Two-Drug Regimen Shines in HIV Treatment Switch Study

A regimen consisting of only two drugs, the integrase inhibitor dolutegravir (Tivicay) and the NNRTI rilpivirine (Edurant), held up well as a maintenance approach in people with HIV who switched from more complex regimens.

By Myles Helfand

What Are the Ethical and Scientific Considerations of Analytical Treatment Interruptions?

Though it may not be the riskiest aspect of HIV cure research, ATI (analytical treatment interruption) is among the more controversial topics in the field right now, noted Karine Dubé, DrPH, of the University of North Carolina at Chapel Hill, at the ...

By Olivia G. Ford

Taking Atripla Three Days a Week Maintains Undetectable HIV Viral Load, Pilot Study Finds

Taking efavirenz/tenofovir/emtricitabine (Atripla) three days a week maintained an undetectable viral load for at least 24 weeks in people who were already virally suppressed for at least two years, according to a small proof-of-concept study present...

By Warren Tong

The Most Important HIV Study at IDWeek 2015

Paul Sax, M.D., breaks down another HIV treatment switching study -- this one from IDWeek 2015 -- the results of which supported switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide plus darunavir (Prezista) for treatment-experien...

By Paul E. Sax, M.D. for NEJM Journal Watch

HIV Remission for More Than 12 Years After Very Early Treatment in French Teenager

An 18-year-old female has been able to maintain an undetectable viral load for more than 12 years after interrupting early antiretroviral treatment, according to a study presented at IAS 2015.

By Warren Tong

Dosing Regimen of 5 Days On and 2 Days Off Controls HIV in Young People

A study showed viral control in the great majority of youth who took their regimen for five days but then skipped two, which may offer younger patients a novel way to keep HIV under control while addressing common adherence issues.

By Project Inform

Markers of Immune Exhaustion Predict Post-Treatment Control in HIV Patients

Biomarkers of immune exhaustion were associated with how long a patient was able to control HIV after treatment was interrupted, according to a study presented at CROI 2015.

By Warren Tong

Viral Rebound Is Significantly Delayed Among Some Who Interrupt HIV Treatment

Is taking a month or two off from antiretroviral therapy truly such a bad thing? If new research presented at IDWeek 2014 is any indication, the argument for or against HIV treatment interruptions may be more nuanced than we thought.

By Myles Helfand

TILT: A Look at the Role of Interleukin-2 in Treatment Interruption Leans Toward the Negative

Most antiretroviral treatment guidelines utilize a CD4+ cell count threshold for the initiation of therapy. Interventions that increase CD4+ cell counts may not only be clinically beneficial, they may also be able to prolong the time off of antiretro...

By Keith Henry, M.D.